Zocitab: Advanced Relief for Major Depressive Disorder
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $20.18 | $201.82 (0%) | 🛒 Add to cart |
| 20 | $17.42 | $403.63 $348.41 (14%) | 🛒 Add to cart |
| 30 | $16.53 | $605.45 $496.01 (18%) | 🛒 Add to cart |
| 40 | $16.09 | $807.27 $643.61 (20%) | 🛒 Add to cart |
| 50 | $15.82
Best per pill | $1009.08 $791.20 (22%) | 🛒 Add to cart |
Synonyms | |||
Zocitab is a prescription medication specifically formulated for the treatment of Major Depressive Disorder (MDD) in adults. As a selective serotonin reuptake inhibitor (SSRI), it works by restoring the balance of serotonin, a natural substance in the brain that helps maintain mental equilibrium. Clinical studies demonstrate its efficacy in significantly reducing the symptoms of depression, improving mood, and enhancing overall quality of life. This medication is intended for use under strict medical supervision as part of a comprehensive treatment plan.
Features
- Active ingredient: Sertraline Hydrochloride
- Available in 25 mg, 50 mg, and 100 mg film-coated tablets
- Bioavailability of approximately 44%
- Peak plasma concentration reached within 4.5–8.4 hours post-administration
- Half-life of approximately 26 hours
- Metabolized hepatically via CYP450 isoenzymes
- Excreted equally in feces and urine
Benefits
- Effectively reduces core symptoms of depression, including low mood and anhedonia
- Helps restore normal sleep patterns and improve energy levels
- Reduces anxiety often associated with depressive episodes
- Improves overall daily functioning and social engagement
- Provides a favorable safety profile with extensive clinical documentation
- Supports long-term maintenance therapy for sustained wellness
Common use
Zocitab is primarily indicated for the treatment of Major Depressive Disorder in adult patients. It may also be prescribed off-label for conditions such as obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), social anxiety disorder, and premenstrual dysphoric disorder (PMDD), following thorough clinical assessment and at the discretion of a healthcare provider.
Dosage and direction
The recommended starting dosage for Zocitab is 50 mg administered orally once daily, either in the morning or evening, with or without food. Dosage may be adjusted based on therapeutic response and tolerability, with increases made in increments of 50 mg at intervals of no less than one week. The maximum recommended dosage is 200 mg per day. Patients should be advised to swallow the tablet whole with water and not to crush or chew it. Dosage adjustments are necessary in patients with hepatic impairment, and lower starting doses are often recommended in such cases.
Precautions
Patients should be monitored closely for clinical worsening, suicidality, or unusual changes in behavior, especially during the initial few months of therapy or following dosage changes. Zocitab may cause activation of mania/hypomania; caution is advised in patients with a history of bipolar disorder. Use with caution in patients with a history of seizures. SSRI use may be associated with hyponatremia, particularly in elderly patients or those taking diuretics. Discontinuation symptoms may occur upon abrupt cessation; gradual tapering is recommended.
Contraindications
Zocitab is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy due to the risk of serotonin syndrome. Concomitant use with pimozide is contraindicated. This medication is also contraindicated in patients with known hypersensitivity to sertraline or any component of the formulation.
Possible side effect
Common adverse reactions (≥5% and at least twice the rate of placebo) include nausea, diarrhea/loose stools, insomnia, somnolence, dry mouth, increased sweating, dizziness, fatigue, tremor, dyspepsia, decreased appetite, and sexual dysfunction (including decreased libido, ejaculatory delay, and anorgasmia). Most side effects are mild to moderate and often diminish with continued therapy.
Drug interaction
Zocitab is a moderate inhibitor of CYP2D6 and may increase concentrations of drugs metabolized by this enzyme (e.g., tricyclic antidepressants, antipsychotics, certain beta-blockers). Concomitant use with other serotonergic drugs (including other SSRIs, SNRIs, triptans, tramadol, and tryptophan) increases the risk of serotonin syndrome. Use with warfarin may require increased monitoring of prothrombin time. Concurrent use with NSAIDs, aspirin, or other drugs affecting coagulation may increase the risk of bleeding.
Missed dose
If a dose is missed, it should be taken as soon as remembered, unless it is close to the time of the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one.
Overdose
Symptoms of overdose may include serotonin syndrome manifestations (agitation, confusion, tachycardia, hyperthermia, diaphoresis, tremors), somnolence, nausea, vomiting, and dizziness. There is no specific antidote for Zocitab overdose; treatment should consist of supportive measures and symptomatic care. Gastric lavage with activated charcoal may be considered if presented early. Ensure adequate airway protection and monitor cardiac function and vital signs.
Storage
Store Zocitab tablets at controlled room temperature, 20–25°C (68–77°F), with excursions permitted between 15–30°C (59–86°F). Keep in the original container, tightly closed, and protect from light and moisture. Keep out of reach of children and pets. Dispose of unused medication properly according to local regulations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Zocitab is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Patients should not initiate, adjust, or discontinue therapy without consulting their physician. Individual results may vary based on patient-specific factors and adherence to prescribed treatment.
Reviews
“After eight weeks on Zocitab, my patient showed remarkable improvement in mood and motivation. The side effect profile was manageable with initial GI discomfort that resolved with continued use.” — Dr. Eleanor Vance, Psychiatrist
“Zocitab has been a cornerstone in my practice for treating moderate to severe MDD. The gradual titration allows for good tolerability, and most patients achieve significant symptom relief by week 4–6.” — Dr. Marcus Thorne, Clinical Psychopharmacologist
“While effective, clinicians should remain vigilant for activation effects in younger adults. In my experience, starting at 25 mg reduces initial anxiety and improves adherence.” — Dr. Lena Petrova, Psychiatric Researcher
“Long-term maintenance with Zocitab has provided sustained remission for many of my patients with recurrent depression. The once-daily dosing supports compliance in chronic management.” — Dr. Robert Chen, Mood Disorders Specialist